{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T08:10:22Z","timestamp":1774512622903,"version":"3.50.1"},"reference-count":12,"publisher":"European Respiratory Society (ERS)","issue":"5","license":[{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/publications.ersnet.org\/user-licence"}],"funder":[{"DOI":"10.13039\/501100006342","name":"Association Vaincre la Mucoviscidose","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006342","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Soci\u00e9t\u00e9 Fran\u00e7aise de la Mucoviscidose"},{"name":"Fili\u00e8re Maladies Rares MUCO-CFTR"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2025,4,4]]},"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1183\/13993003.02490-2024","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T01:35:22Z","timestamp":1745458522000},"page":"2402490","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world monitoring of elexacaftor\/tezacaftor\/ivacaftor trough concentrations in adults with cystic fibrosis"],"prefix":"10.1183","volume":"65","author":[{"given":"Paulette","family":"Magnas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sihem","family":"Benaboud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Da Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4385-5888","authenticated-orcid":false,"given":"Cl\u00e9mence","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reem","family":"Kanaan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6828-608X","authenticated-orcid":false,"given":"Nicolas","family":"Carlier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Honor\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Fesenbeckh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naim","family":"Bouazza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franz","family":"Foissac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Marc","family":"Treluyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0903-9828","authenticated-orcid":false,"given":"Pierre-R\u00e9gis","family":"Burgel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"81","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"key":"2025052201351825000_65.5.2402490.1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41572-024-00538-6","article-title":"Cystic fibrosis","volume":"10","author":"Mall","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"2025052201351825000_65.5.2402490.2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02437-2022"},{"key":"2025052201351825000_65.5.2402490.3","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S2213-2600(24)00208-X","article-title":"The expanded French compassionate programme for elexacaftor-tezacaftor-ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study","volume":"12","author":"Burgel","year":"2024","journal-title":"Lancet Respir Med"},{"key":"2025052201351825000_65.5.2402490.4","unstructured":"US Food and Drug Administration . Center for Drug Evaluation and Research Clinical Pharmacology and Biopharmaceutics review(s), Elexacaftor\/ Tezacaftor\/Ivacaftor. www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/212273Orig1s000MultidisciplineR.pdf"},{"key":"2025052201351825000_65.5.2402490.5","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3390\/jpm11060458","article-title":"CFTR modulators: does one dose fit all?","volume":"11","author":"van der Meer","year":"2021","journal-title":"J Pers Med"},{"key":"2025052201351825000_65.5.2402490.6","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.jcf.2024.04.013","article-title":"Heterogeneity in response to elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis","volume":"23","author":"Alicandro","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2025052201351825000_65.5.2402490.7","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01662"},{"key":"2025052201351825000_65.5.2402490.8","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202011-4153OC"},{"key":"2025052201351825000_65.5.2402490.9","doi-asserted-by":"crossref","first-page":"116322","DOI":"10.1016\/j.jpba.2024.116322","article-title":"A rapid LC-MS\/MS method for the simultaneous quantification of ivacaftor, lumacaftor, elexacaftor, tezacaftor, hexyl-methyl ivacaftor and ivacaftor carboxylate in human plasma","volume":"248","author":"Zheng","year":"2024","journal-title":"J Pharm Biomed Anal"},{"key":"2025052201351825000_65.5.2402490.10","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A phase 3 open-label study of elexacaftor\/tezacaftor\/ivacaftor in children 6 through 11\u2005years of age with cystic fibrosis and at least one F508del allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2025052201351825000_65.5.2402490.11","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3390\/jpm14101065","article-title":"Therapeutic drug monitoring of elexacaftor, tezacaftor, and ivacaftor in adult people with cystic fibrosis","volume":"14","author":"Naehrig","year":"2024","journal-title":"J Pers Med"},{"key":"2025052201351825000_65.5.2402490.12","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.jcf.2024.03.010","article-title":"Correlation between trough concentration and AUC for elexacaftor, tezacaftor and ivacaftor","volume":"23","author":"Vonk","year":"2024","journal-title":"J Cyst Fibros"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.02490-2024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T08:35:33Z","timestamp":1747902933000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.02490-2024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,23]]},"references-count":12,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,22]]},"published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1183\/13993003.02490-2024"],"URL":"https:\/\/doi.org\/10.1183\/13993003.02490-2024","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,23]]}}}